Online inquiry

IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6894MR)

This product GTTS-WQ6894MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CX3CL1 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_002996.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6376
UniProt ID P78423
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ6894MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2319MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ALXN6000
GTTS-WQ13246MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-05335810
GTTS-WQ1557MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACE-041
GTTS-WQ635MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 8c10
GTTS-WQ13792MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-10933
GTTS-WQ12298MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ9374MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ16005MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ZW-25
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW